Detection of Virulence Factors and Antimicrobial Susceptibility among Clinical Strains of Enterococcus faecalis.

IF 2.6 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current pharmaceutical biotechnology Pub Date : 2025-09-26 DOI:10.2174/0113892010388498250818114856

Muhamad Ali K Shakhatreh, Hana Hamad Rabaiah, Omar F Khabour, Jacob H Jacob, Karem H Alzoubi

{"title":"Detection of Virulence Factors and Antimicrobial Susceptibility among Clinical Strains of Enterococcus faecalis.","authors":"Muhamad Ali K Shakhatreh, Hana Hamad Rabaiah, Omar F Khabour, Jacob H Jacob, Karem H Alzoubi","doi":"10.2174/0113892010388498250818114856","DOIUrl":null,"url":null,"abstract":"Introduction: Enterococci are common commensals in the gastrointestinal tract and are opportunistic organisms that can cause urinary tract infections, bacteremia, endocarditis, and pelvic infections. The study aimed to investigate antibiotic resistance, biofilm formation, and the presence and expression of virulence factors in clinical isolates of E. faecalis from Jordan.Methods: Clinical isolates (n=89) of E. faecalis isolated from patients in Jordan were collected. Antibiotic resistance, biofilm formation, and the presence/expression of virulence genes asa1, gelE, esp, cylA, and efaA were examined.Results: High resistance of E. faecalis was detected for ampicillin (98.9%), followed by quinupristin-dalfopristin (96.6%), tetracycline (83.1%), erythromycin (78.6%), and rifampin (68.5%). Most isolates (93.3%) were found to be biofilm producers. The prevalence of virulence genes was efaA (77.5%), asa1 (77.5%), gelE (69.7%), esp (50.6%), and cylA (30%). About 25.8% of the isolates were found to be gelatinase producers. In addition, hemolysin production was observed in 37.1% of the isolates.Discussion: The esp gene was associated with tetracycline resistance. The asa1 gene was associated with susceptibility to vancomycin. CylA was associated with resistance to tetracycline and erythromycin, as well as susceptibility to ciprofloxacin and gentamicin. The presence of gelE was associated with susceptibility to chloramphenicol, tetracycline, levofloxacin, and erythromycin. The cylA gene was associated with esp and asa1 genes, while the efaA was found to be associated with gelE and asa1 genes (P<0.05). Finally, biofilm formation was not associated with antimicrobial resistance (P > 0.05).Conclusions: The antibiotic resistance profiles and associated genes of E. faecalis isolates from Jordanian patients were reported. The efaA, asa1, and gelE virulence genes were highly prevalent among the isolates. The present findings can be used in the management of E. faecalis infection in Jordan.","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010388498250818114856","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Enterococci are common commensals in the gastrointestinal tract and are opportunistic organisms that can cause urinary tract infections, bacteremia, endocarditis, and pelvic infections. The study aimed to investigate antibiotic resistance, biofilm formation, and the presence and expression of virulence factors in clinical isolates of E. faecalis from Jordan.

Methods: Clinical isolates (n=89) of E. faecalis isolated from patients in Jordan were collected. Antibiotic resistance, biofilm formation, and the presence/expression of virulence genes asa1, gelE, esp, cylA, and efaA were examined.

Results: High resistance of E. faecalis was detected for ampicillin (98.9%), followed by quinupristin-dalfopristin (96.6%), tetracycline (83.1%), erythromycin (78.6%), and rifampin (68.5%). Most isolates (93.3%) were found to be biofilm producers. The prevalence of virulence genes was efaA (77.5%), asa1 (77.5%), gelE (69.7%), esp (50.6%), and cylA (30%). About 25.8% of the isolates were found to be gelatinase producers. In addition, hemolysin production was observed in 37.1% of the isolates.

Discussion: The esp gene was associated with tetracycline resistance. The asa1 gene was associated with susceptibility to vancomycin. CylA was associated with resistance to tetracycline and erythromycin, as well as susceptibility to ciprofloxacin and gentamicin. The presence of gelE was associated with susceptibility to chloramphenicol, tetracycline, levofloxacin, and erythromycin. The cylA gene was associated with esp and asa1 genes, while the efaA was found to be associated with gelE and asa1 genes (P<0.05). Finally, biofilm formation was not associated with antimicrobial resistance (P > 0.05).

Conclusions: The antibiotic resistance profiles and associated genes of E. faecalis isolates from Jordanian patients were reported. The efaA, asa1, and gelE virulence genes were highly prevalent among the isolates. The present findings can be used in the management of E. faecalis infection in Jordan.

查看原文本刊更多论文

粪肠球菌临床菌株毒力因子及药敏检测。

肠球菌是胃肠道中常见的共生菌，是一种机会性生物，可引起尿路感染、菌血症、心内膜炎和盆腔感染。本研究旨在研究约旦粪肠杆菌临床分离株的抗生素耐药性、生物膜形成以及毒力因子的存在和表达。方法：收集约旦患者临床分离的粪肠球菌89株。检测了抗生素耐药性、生物膜形成以及毒力基因asa1、gelE、esp、cylA和efaA的存在/表达。结果：粪肠球菌对氨苄西林的耐药率为98.9%，其次为奎奴普司汀-达佛普司汀（96.6%）、四环素（83.1%）、红霉素（78.6%）和利福平（68.5%）。大多数分离株（93.3%）为生物膜生产者。毒力基因为efaA（77.5%）、asa1（77.5%）、gelE（69.7%）、esp（50.6%）和cylA（30%）。25.8%的分离菌为明胶酶产生菌。此外，37.1%的分离株可产生溶血素。讨论：esp基因与四环素耐药有关。asa1基因与万古霉素易感性相关。CylA与对四环素和红霉素的耐药性以及对环丙沙星和庆大霉素的敏感性有关。gelE的存在与对氯霉素、四环素、左氧氟沙星和红霉素的敏感性有关。cylA基因与esp和asa1基因相关，efaA基因与gelE和asa1基因相关（P < 0.05）。结论：报道了从约旦患者分离的粪肠杆菌的抗生素耐药谱和相关基因。efaA、asa1和gelE毒力基因在分离株中高度流行。本研究结果可用于约旦粪肠杆菌感染的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical biotechnology 医学-生化与分子生物学

CiteScore

5.60

自引率

3.60%

发文量

203

审稿时长

6 months

期刊介绍： Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include: DNA/protein engineering and processing Synthetic biotechnology Omics (genomics, proteomics, metabolomics and systems biology) Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes) Drug delivery and targeting Nanobiotechnology Molecular pharmaceutics and molecular pharmacology Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes) Pharmacokinetics and pharmacodynamics Applied Microbiology Bioinformatics (computational biopharmaceutics and modeling) Environmental biotechnology Regenerative medicine (stem cells, tissue engineering and biomaterials) Translational immunology (cell therapies, antibody engineering, xenotransplantation) Industrial bioprocesses for drug production and development Biosafety Biotech ethics Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.